search

Active clinical trials for "Leber Congenital Amaurosis"

Results 1-10 of 29

Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)

Leber Congenital Amaurosis

The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutationsin RPE65 gene.

Recruiting9 enrollment criteria

An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety...

Leber Congenital Amaurosis 10Blindness9 more

PQ-110-005 (BRIGHTEN) is an open-label, dose escalation and double-masked, randomized, controlled study evaluating safety and tolerability of sepofarsen administered via intravitreal (IVT) injection in pediatric subjects (<8 years of age) with LCA10 due to the c.2991+1655A>G mutation over 24 months of treatment.

Recruiting9 enrollment criteria

Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital...

Retinitis PigmentosaLeber Congenital Amaurosis

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects Investigators will also conduct a Natural History Study (OCU400-104)i This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 24 subjects in the OCU400-101 and 100 subjects in the OCU400-104 study.

Recruiting37 enrollment criteria

Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis...

Leber Congenital AmaurosisLCA1 more

Primary Objective: To evaluate the safety and tolerability of ascending doses of SAR439483 administered as a unilateral subretinal injection in patients with Leber Congenital Amaurosis (LCA) caused by autosomal recessive guanylate cyclase 2D (GUCY2D) mutations (GUCY2D-LCA). Secondary Objective: To evaluate the efficacy of ascending doses of SAR439483 administered as a unilateral subretinal injection in patients with GUCY2D-LCA.

Active22 enrollment criteria

Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations

Amaurosis of LeberRetinal Diseases

A recombinant adeno-associated virus serotype 2 (rAAV2) vector has been altered to carry the human RPE65 (hRPE65) gene. This vector has been shown to restore vision in animal models that resemble human RPE65-associated Leber congenital amaurosis (LCA), an incurable retinal degeneration that causes severe vision loss. The proposed study is an open label, Phase I clinical trial of subretinal rAAV2-CBSB-hRPE65 administration to individuals with RPE65-associated retinal disease. Five cohorts will be included in this trial. Cohorts 1, 2 and 4 will consist of individuals 18 years of age and older. Cohorts 3 and 5 will consist of individuals between the ages of 8 and 17, inclusive. Enrollment in Cohorts 3 and 5 will begin only after confirming the safety of rAAV2-CBSB-hRPE65 administration in the older groups of participants. This trial will lead to a greater understanding of the safety and thereby potential value of gene transfer in RPE65-associated retinal disease and will have implications for other forms of retinal degenerative disease amenable to this type of intervention. The goal of this clinical trial is to determine the safety of uniocular subretinal administration of rAAV2-CBSB-hRPE65 in individuals with RPE65-associated retinal disease. Ocular and systemic toxicity will be assessed prior to and following vector administration to determine if there are adverse changes that may be associated with vector administration.

Active20 enrollment criteria

Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis

Inherited Retinal Dystrophy Due to RPE65 MutationsLeber Congenital Amaurosis

The study is a Phase 3, open-label, randomized controlled trial of gene therapy intervention by subretinal administration of AAV2-hRPE65v2 (voretigene neparvovec-rzyl). At least twenty-four subjects, three years of age or older, will be recruited. The intervention group will receive AAV2-hRPE65v2 at either The Children's Hospital of Philadelphia or University of Iowa to determine if it improves visual and retinal function in individuals with RPE65 gene mutations.

Active17 enrollment criteria

Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA)...

Leber Congenital Amaurosis

The study is a follow-on to a Phase 1 dose-escalation and safety study.

Active13 enrollment criteria

Single Ascending Dose Study in Participants With LCA10

Leber Congenital Amaurosis 10Inherited Retinal Dystrophies6 more

The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of EDIT-101 administered via subretinal injection in participants with LCA10 caused by a homozygous or compound heterozygous mutation involving c.2991+1655A>G in intron 26 of the CEP290 gene ("LCA10-IVS26").

Active12 enrollment criteria

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen...

Leber Congenital Amaurosis 10Blindness9 more

The purpose of this double-masked, randomized, controlled, multiple-dose study is to evaluate the efficacy, safety, tolerability and systemic exposure of sepofarsen (QR-110) administered via intravitreal injection in subjects with Leber's Congenital Amaurosis (LCA) due to the CEP290 p.Cys998X mutation after 24 months of treatment

Active32 enrollment criteria

A Safety and Efficacy Study of HG004 in Subjects With Leber Congenital Amaurosis

Leber Congenital AmaurosisInherited Retinal Diseases Caused by RPE65 Mutations

The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutations in RPE65 gene.

Not yet recruiting13 enrollment criteria

Need Help? Contact our team!


We'll reach out to this number within 24 hrs